JPY 3,476.00
-101.00 (-2.82%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 6988.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPFNCT03538301results2023-12-11Number of Participants Discontinuing Study Treatment Due to TEAEsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose) · Other: Other: Placebo | Idiopathic Pulmonary Fibrosis | 123 | 2022-08-24actual | 2023-12-11 |
| Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male VolunteersNCT02955030Number of subjects with local and systemic reactions and subjects reporting one or more adverse eventsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: NSV0001, Influenza HA vaccine "Biken HA", Placebo | Influenza | 90 | Mar 2017actual | 2017-09-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19